Based on the human, societal, and financial burdens of obesity, as well as the costs and adherence challenges of GLP‐1 therapy, more comprehensive weight management programs and research on their optimal use are needed in healthcare. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.